Case study: ARGX-110
Cusatuzumab (ARGX-110) was designed as a POTELLIGENT®-equipped SIMPLE Antibody™ targeting CD70.
It builds on the translational research of Prof. Adrian Ochsenbein, M.D. at Bern University Hospital, demonstrating the role of the CD70-CD27 pathway in leukemic stem cell biology. A Phase 1 trial showed encouraging tolerability and activity supporting further development of cusatuzumab.
Further evidence about synergistic activity between cusatuzumab and the current standard of care (azacytidine; venclexta) support the current clinical development path in AML and higher-risk MDS. In December 2018, argenx entered into a global collaboration and licensing agreement with Janssen R&D with the goal to accelerate and broaden the development plan for cusatuzumab.